Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy with Intravenous Immunoglobulin (IVIG). The pharmacokinetics of TA-650 is also examined.
Epistemonikos ID: 688413f30f9a388a01b95ee3d7bd2163a5a89c32
First added on: May 10, 2024